Products

What will AGI do for Barbexaclone?

This classification denotes an anticonvulsant agent with the molecular formula C12H12N2O3.C10H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 291GX1YB65, chemically known as 1,1-cyclohexyl-2-methylaminopropane-5,5-phenylethylbarbiturate but generally known as barbexaclon, which bears US NIH Compound Identifier 71196. European Medicines Agency schedules Barbexaclone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06101MIG. The term BARBEXACLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules barbexaclon in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule barbexaclone under HS 29335400 and SITC kg. As of Q4 2014, BARBEXACLONE remains the US FDA Preferred Term for this commodity. Barbexaclone bears US NLM identifiers UMLS ID C0105205 and NCI Concept Code C77998. SMILES: CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2.CC(CC1CCCCC1)NC.

How AGI delivers it

Four ways AGI delivers for Barbexaclone

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Barbexaclone, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Barbexaclone, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Barbexaclone connects

measured by

  • Assay Puritymodel
  • Melting Pointmodel
  • Particle Sizemodel
  • Residual Solventmodel